<DOC>
	<DOC>NCT01655511</DOC>
	<brief_summary>This study in healthy male and female volunteers will investigate the safety and tolerability of three increasing oral doses of tafamidis</brief_summary>
	<brief_title>Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Healthy, males or females, 21 to 55 years old. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). Condition affecting drug absorption. Blood pressure or ECG abnormalities. Recent treatment with an investigational, prescription, or nonprescription drug</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>